Inside an abortion clinic when the Supreme Court overturned Roe – Oil City Derrick

My assignment was to illustrate a story on how blue states might receive an influx of abortion patients from neighboring red states after Roe v. Wade was overturned. That's why I was in New Mexico last Thursday, when many thought the Supreme Court would issue its ruling.

I had emailed two clinics, including the doctors who worked there. After many email exchanges, the Center for Reproductive Health at the University of New Mexico in Albuquerque agreed to let me come. The doctors and staff welcomed me, granting me more access than I had expected.

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

kAmx 2CC:G65 2E g 2]>] H:E9 t=:K236E9 v:3D@?[ >J 6D4@CE 7C@> E96 F?:G6CD:EJ[ H2:E:?8 7@C >6 😕 E96 A2C<:?8 =@E] x D@@? >6E 2 ?6H 72>:=J A9JD:4:2? 2?5 @E96C >65:42= DE277]k^Am

kAm(92E F?7@=565 @G6C E92E 52J 2?5 E96 ?6IE 6>3@5J E96 492==6?86D @7 36:?8 2 A9@E@;@FC?2=:DE 😕 DF49 D:EF2E:@?D 9@H E@ A@CEC2J C62=:EJ 244FC2E6=J 3FE 4@>A2DD:@?2E6=J[ AC6D6CG:?8 D@>6 AC:G24J 7@C DF3;64ED 😕 E96:C >@DE A6CD@?2= 2?5 GF=?6C23=6 >@>6?ED]k^Am

kAm(:E9:? 2 76H >:?FE6D[ x H2D 23=6 E@ A9@E@8C2A9 2 adJ62C@=5 A2E:6?E 5FC:?8 96C F=EC2D@F?5 AC@465FC6] %9@F89 D96 5:5?VE H2?E 96C 7246 D9@H?[ E96 A9@E@D 2C6 :?E:>2E6 2?5 E6== 2 DE@CJ]k^Am

kAmpE gib` 2]>] >J A9@?6 3682? E@ G:3C2E6]k^Am

kAmx =@@<65 5@H? 2E E96 42==6C xs[ 2?5 :E H2D @FC w@FDE@? 3FC62F 49:67 |@==J w6??6DDJu:D<6 @? E96 =:?6]k^Am

kAmQx E9:?< x 42? 86E FD :?E@ 2? 23@CE:@? 4=:?:4 :? $2? p?E@?:@[ %6I2D[ E@>@CC@H[Q D96 D2:5]k^Am

kAmx? 2 H9:DA6C65 E@?6[ x D2:5[ Q(6 ?665 E@ 8@]Qk^Am

kAm(6 5:5?VE 6 r@FCE H@F=5 :DDF6 :ED CF=:?8] }@E9:?8 H2D 46CE2:?] x H2D E9:?<:?8 E@ >JD6=7 9@H :>A@CE2?E 2?5 9:DE@C:4 :E H@F=5 36 E@ 36 :?D:56 2 4=:?:4 H96? E96 564:D:@? 42>6 5@H?[ 6DA64:2==J 😕 2 C65 DE2E6]k^Am

kAmx AFE >J A9@?6 :?E@ >J 324< A@4<6E 2?5 BF:4<=J 962565 324< E@ E96 DE277 H@C< 2C62[ H96C6 x A9@E@8C2A965 E96 5@4E@C 2?5 96C C6D:56?E G:6H:?8 2? F=EC2D@F?5 @7 2 bhJ62C@=5 H@>2? H9@ H2D D66<:?8 2? 23@CE:@?] %96 H@>2? 2=C625J 925 7@FC 49:=5C6?]k^Am

kAm%96 H@>2? 28C665 E@ =6E >6 A9@E@8C2A9 96C AC@465FC6 H:E9@FE C6G62=:?8 96C :56?E:EJ] x 6?E6C65 E96 6I2> C@@>[ H96C6 `hg_D >FD:4 H2D A=2J:?8 D@7E=J E9C@F89 46:=:?8 DA62<6CD] %96 C@@> H2D 52C< 6I46AE 7@C E96 D>2== 2?5 3C:89E 6I2> C@@> =:89E]k^Am

kAmx H2?E65 E@ 42AEFC6 E96 >@@5 @7 E96 @?6 =:89E D@FC46[ D@ x 25;FDE65 E96 x$~ @? >J 42>6C2j E92E 4@?EC@=D E96 2>@F?E @7 =:89E =6E :?] x DE@@5 2E E96 324< @7 E96 C@@>] %96 2?8=6 5:5 ?@E C6G62= E96 H@>2?VD :56?E:EJ]k^Am

kAm%96 5@4E@C 2?5 96C C6D:56?E H@C<65 :? E2?56> 2D 2 ?FCD6 2DD:DE65 5FC:?8 E96 AC@465FC6]k^Am

kAmQpC6 J@F 5@:?8 ~znQ E96 5@4E@C 2D<65 E96 A2E:6?E @? E96 6I2> E23=6] %96 H@>2? 24

kAmpE @?6 A@:?E[ E96 ?FCD6 96=5 E96 A2E:6?EVD 92?5 2?5 86?E=J CF3365 96C 9625]k^Am

kAm|J pAA=6 (2E49 3682? E@ G:3C2E6]k^Am

kAmQx ?665 E@ =62G6 D@@?[Q D2:5 E96 E6IE >6DD286 7C@> v:3D@?[ >J 6D4@CE :?D:56 E96 4=:?:4] $96 H2D H2:E:?8 @FED:56 E96 6I2> C@@>]k^Am

kAmQs@ J@F >:?5 :7 x DE2J 😕 96C6 d >@C6 >:?D 2?5 >2J36 p?86=2 42? 6D4@CE >6 @FEnQ x HC@E6 324<]k^Am

kAmQ&?7@CEF?2E6=J[ E92EVD ?@E E96 A@=:4J] x 92G6 E@ 36 H:E9 J@F[Q D96 C6A=:65k^Am

kAmQb >@C6 >:?FE6D[ @<2JnQk^Am

kAmx H2?E65 E@ DE2J F?E:= E96 6?5 @7 E96 H@>2?VD AC@465FC6[ 3FE 27E6C b >:?FE6D x E:AE@65 @FE @7 E96 C@@>]k^Am

kAmx 8@E 😕 >J C6?E2= 42C 2?5 5C@G6 E@ 2 D925J A2C<:?8 DA@E] x ?66565 E@ 86E 4@?7:C>2E:@? E92E x 925 A6C>:DD:@? E@ A9@E@8C2A9 :?D:56 E96 %6I2D 4=:?:4 E96 ?6IE >@C?:?8 2?5 7:?5 2 H2J E@ 86E E96C6 E92E ?:89E]k^Am

kAmx =67E 2 G@:46>2:= 7@C E96 p?5C62 v2==68@D[ 6I64FE:G6 5:C64E@C @7 E96 4=:?:4 😕 $2? p?E@?:@[ 2?5 D6?E 96C 2 E6IE >6DD286]k^Am

kAmx H2:E65] %6? >:?FE6D A2DD65]k^Am

kAm%96?[ 2 E6IE 7C@> p?5C62 2CC:G65] p7E6C 2 324< 2?5 7@CE9[ D96 28C665 E@ =6E FD 4@>6 E@ E96 4=:?:4 7:CDE E9:?8 😕 E96 >@C?:?8] x 962565 E@ E96 2:CA@CE] xE H@F=5 E2<6 >6 D:I 9@FCD E@ 86E 7C@> p=3FBF6CBF6 E@ $2? p?E@?:@ E92E ?:89E]k^Am

kAm(96? x 2CC:G65 2E E96 p=2>@ (@>6?VD #6AC@5F4E:G6 $6CG:46D 2E h 2]>] uC:52J[ A2E:6?ED H6C6 2=C625J =:?65 FA @FED:56 E96 5@@C]k^Am

kAm!C@E6DE6CD H6C6 D4C62>:?8 E9C@F89 2 >682A9@?6 @? E96 D:56H2=< ?62C E96 4=:?:4]k^Am

kAmQ*@F 5@?VE 92G6 E@ 8@ :?PQ E96 24E:G:DED A=62565 H:E9 E96 H@>6?] Q%96J >FC56C 323:6DPQk^Am

kAm|@==J 2?5 x H6C6 6D4@CE65 :?E@ 2 324< @77:46 E@ >66E sC] p=2? qC2:5[ E96 4=:?:4VD @H?6C] %96? 2E hi`b[ 6G6CJE9:?8 492?865]k^Am

kAmqC2:5VD 52F89E6C[ v2==68@D[ A@<65 96C 9625 :? E96 5@@C]k^Am

kAmQxEVD @FE] %96 564:D:@?VD @FE[Q D96 D2:5] QuF== @G6CEFC?]Qk^Am

kAmqC2:5 4FCD65] %96? 96 3682? E@ E62C FA] x H2D 23=6 E@ D?2A @?6 7C2>6 @7 qC2:5 2D E96 E62CD 42>6] %96?[ 96 =@@<65 2E >6 DE6C?=J 2?5 D2:5[ Qr@>6 @?PQk^Am

kAmx @>6?E x 925 E@ AFE >J 42>6C2 5@H?] x H2?E65 E@ 42AEFC6 9:D 6>@E:@?D 2E E92E >@>6?E[ 3FE 2E E96 D2>6 E:>6 x 5:5?VE H2?E E@ 2?86C qC2:5 2?5 9FCE >J 492?46D @7 DE2J:?8 😕 E96 4=:?:4 =@?86C]k^Am

kAm|J >:?5 H2D C24:?8] x ?66565 E@ 86E E@ E96 H2:E:?8 C@@>[ H96C6 A2E:6?ED H6C6 F?2H2C6 @7 H92E 925 ;FDE 92AA6?65]k^Am

kAmxE H2D 2 56=:42E6 32=2?46 7@C >6] x AC@>:D65 E96 4=:?:4 25>:?:DEC2E@C x H@F=5 C6DA64E A2E:6?E 4@?7:56?E:2=:EJ 2?5 ?@E A9@E@8C2A9 2?J A2E:6?ED H9@ 5:5 ?@E 8:G6 FD A6C>:DD:@? E@ 5@ D@] tG6? E9@F89 E9:D H2D 2 9:DE@C:4 >@>6?E[ x 925 E@ DE:4< E@ >J AC@>:D6]k^Am

kAm~? >J H2J E@ E96 H2:E:?8 C@@>[ x A9@E@8C2A965 2 DE277 >6>36C[ H9@ H2D G:D:3=J FAD6E]k^Am

kAmqC2:5 6?E6C65 E96 H2:E:?8 C@@> H:E9 v2==68@D 3J 9:D D:56] pD x A9@E@8C2A965 qC2:5 7C@> 24C@DD E96 C@@>[ A2E:6?ED AFE E96:C 9625D 5@H? 😕 5:DEC6DD 2D 96 DA@<6]k^Am

kAmQ%96 $FAC6>6 r@FCE ;FDE @G6CEFC?65 #@6 G6CDFD (256] %96JVG6 E2<6? 2H2J J@FC C:89E E@ 49@@D6 H92E E@ 5@ H:E9 J@FC 3@5J[Q 96 D2:5 E@ E96 H@>6?]k^Am

kAmQ&?7@CEF?2E6=J[ >J 92?5D 2C6 E:65[Q qC2:5 D2:5[ 6IA=2:?:?8 E96 C:D

kAm%96 4=:?:4 4@F=5 ?@ =@?86C AC@G:56 23@CE:@? D6CG:46D]k^Am

kAmx >@G65 @G6C E@ H96C6 x D2H 2 A2E:6?E[ D:EE:?8 H:E9 2 3=2?< DE2C6] (:E9 >J 42>6C2 @? D:=6?E >@56[ x A9@E@8C2A965 96C] pD D96 =67E E96 4=:?:4[ x 7@==@H65 96C @FED:56 E@ 86E 96C ?2>6] $96 D2:5 x 4@F=5 FD6 96C 7:CDE ?2>6[ {:K]k^Am

kAmpD E96 62C=J >@C?:?8 A2E:6?ED 7:=65 @FE @7 E96 4=:?:4 DEF??65[ >@C6 7:=65 😕 F?2H2C6 E92E 😕 23@CE:@? H2D :==682= ?@H 😕 %6I2D]k^Am

kAm!2E:6?E pAC:= #66D6[ c`[ 2CC:G65 6I24E=J @?6 9@FC 27E6C E96 564:D:@?] $96 2=C625J 92D E9C66 49:=5C6?]k^Am

kAmp? 6>@E:@?2= DE2776C E@=5 96C E96 ?6HD]k^Am

kAmQ$@ H6 92G6 E@ 8@ @FE @7 DE2E6nQ #66D6 2D<65] Q%9:D :D :?D2?6]Qk^Am

kAm#66D6 H2D 23@FE E@ =62G6 H96? D96 ?@E:465 E92E E96 DE2776C H9@ 925 96=A65 96C H2D 4CJ:?8] $96 9F8865 E96 DE2776C]k^Am

kAmQ*@F 8FJD 92G6 5@?6 D@ >F49 8@@5 H@C< 7@C A6@A=6] $@ <66A E92E :? J@FC 962CE[Q #66D6 D2:5] Qs@?VE 8:G6 FA E96 7:89E]Qk^Am

kAmp?@E96C A2E:6?E[ H9@ H2D 2=D@ FAD6E[ D2E 😕 2 H2:E:?8 C@@> 492:C 2?5 4C:65 2D 2 DE2776C EC:65 E@ 4@>7@CE 96C] x A9@E@8C2A965 96C E9C@F89 E96 8=2DD 😕 E96 C646AE:@?:DEVD 2C62]k^Am

kAm%H@ 9@FCD 27E6C #@6 H2D @G6CEFC?65[ E96 H2:E:?8 C@@> 2E p=2>@ (@>6?VD #6AC@5F4E:G6 $6CG:46D H2D 6>AEJ]k^Am

kAmk^Am

kAma_aa {@D p?86=6D %:>6D] ':D:E k2 9C67lQ9EEADi^^HHH]=2E:>6D]4@>^Qm=2E:>6D]4@>k^2m] s:DEC:3FE65 3J k2 9C67lQ9EEADi^^HHH]EC:3F?64@?E6?E286?4J]4@>Qm%C:3F?6 r@?E6?E p86?4J[ {{r]k^2mk^Am

Read the original:
Inside an abortion clinic when the Supreme Court overturned Roe - Oil City Derrick

Julie Person Joins Third Harmonic Bio as Chief Administrative Officer

CAMBRIDGE, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- Third Harmonic Bio, a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT inhibitor for the treatment of severe allergy and inflammation, today announced the appointment of Julie Person to chief administrative officer. Ms. Person brings more than 20 years of experience in building biopharma organizations that align people practices with strategy to drive successful outcomes for patients and teams. In her role, Ms. Person will hold leadership responsibilities for human resources, corporate communications and facilities.

Read the original:
Julie Person Joins Third Harmonic Bio as Chief Administrative Officer

Elevar Therapeutics Names Dr. Jan M. Van Tornout Chief Medical Officer, Dr. Gordon Schooley Chief Regulatory Officer

SALT LAKE CITY, June 28, 2022 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced the hiring of Jan M. Van Tornout, M.D., MSc., as chief medical officer, and Gordon Schooley, Ph.D., as chief regulatory officer.

Read more:
Elevar Therapeutics Names Dr. Jan M. Van Tornout Chief Medical Officer, Dr. Gordon Schooley Chief Regulatory Officer

BioPorto Achieves Targeted Enrollment in Clinical Study Supporting FDA De Novo Submission for The NGAL Test in the U.S.

COPENHAGEN, Denmark and BOSTON, June 28, 2022 (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced its achievement of targeted subject enrollment for the third part of a 3-part clinical study to support a U.S. Food and Drug Administration (FDA) De Novo submission for use of The NGAL Test in identifying patients under the age of 22 at risk for Acute Kidney Injury (AKI).

More:
BioPorto Achieves Targeted Enrollment in Clinical Study Supporting FDA De Novo Submission for The NGAL Test in the U.S.

89bio Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)

- Trial met primary endpoint demonstrating statistically significant and clinically meaningful reductions across all doses (63% at the 27mg QW dose; p<0.001) in triglycerides (TG) from baseline; results were consistent in patients on or not on background therapy -

Read the original here:
89bio Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock, Pre-Funded Warrants and Warrants

SAN FRANCISCO, June 28, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it has commenced an underwritten public offering of $75 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, and accompanying warrants to purchase shares of its common stock. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities to be sold in the offering are being offered by 89bio.

See the original post here:
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock, Pre-Funded Warrants and Warrants